Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog

Acquisition of chemoresistance and metastatic phenotype are the major causes of treatment failure and mortality in head and neck squamous cell carcinoma (HNSCC) patients. Histone deacetylases (HDACs) have been shown to be overexpressed in many tumor types and directly linked to poor prognosis. In this study, we demonstrate that HDACs are markedly elevated in HNSCC. HDACs expression was further increase in cisplatin resistant cell lines (CisR). In addition, cisplatin-resistant cells showed enhanced stem cell properties and tumor metastasis. Depletion of HDAC1 and 2 in CisR cell lines significantly reversed cisplatin resistance and tumorsphere formation. Next, we tested the efficacy of Suberoylanilide hydroxamic acid (SAHA), an HDAC inhibitor, by using both in vitro and in vivo models. SAHA significantly inhibited cell proliferation and synergistically enhanced the anti-proliferative effects of cisplatin. In addition, SAHA significantly decreased tumorsphere formation by markedly reducing nanog expression. In a SCID mouse xenograft model, SAHA significantly enhanced the anti-tumor effects of cisplatin treatment with no added systemic toxicity. Furthermore, SAHA and cisplatin combination treatment significantly decreased tumor metastasis and nanog expression, in vivo. Taken together, our results suggest that targeting HDACs with SAHA could be an effective treatment strategy for the treatment of HNSCC patients.

[1]  E. Appella,et al.  The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis , 2014, Oncogene.

[2]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[3]  T. Teknos,et al.  Highly aggressive human papillomavirus-related oropharyngeal cancer: clinical, radiologic, and pathologic characteristics. , 2013, Oral surgery, oral medicine, oral pathology and oral radiology.

[4]  A. Mapp,et al.  Phosphorylation of Nanog is Essential to Regulate Bmi1 and Promote Tumorigenesis , 2013, Oncogene.

[5]  H. Quon,et al.  Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  L. Chirieac,et al.  Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. , 2012, Oral oncology.

[7]  A. Yadav,et al.  YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels , 2012, Molecular Cancer Therapeutics.

[8]  N. L. La Thangue,et al.  HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications , 2012, Immunology and cell biology.

[9]  J. Klijanienko,et al.  Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[10]  M. Chou,et al.  Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[11]  K. Jeong,et al.  Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. , 2011, Oncology reports.

[12]  Gabriel Wong,et al.  Stem Cell Marker (Nanog) and Stat-3 Signaling Promote MicroRNA-21 Expression and Chemoresistance in Hyaluronan/CD44-activated Head and Neck Squamous Cell Carcinoma Cells , 2011, Oncogene.

[13]  J. Shen,et al.  NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation , 2011, Oncogene.

[14]  C. Nutting,et al.  Head and neck cancer—Part 1: Epidemiology, presentation, and prevention , 2010, BMJ : British Medical Journal.

[15]  N. Kalavrezos,et al.  Current trends and future perspectives in the surgical management of oral cancer. , 2010, Oral oncology.

[16]  S. Merajver,et al.  RhoC Expression and Head and Neck Cancer Metastasis , 2009, Molecular Cancer Research.

[17]  T. Carey,et al.  Genotyping of 73 UM‐SCC head and neck squamous cell carcinoma cell lines , 2009, Head & neck.

[18]  J. You,et al.  Depletion of embryonic stem cell signature by histone deacetylase inhibitor in NCCIT cells: involvement of Nanog suppression. , 2009, Cancer research.

[19]  C. Chiang,et al.  Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. , 2009, Oral oncology.

[20]  S. Kadam,et al.  A Positive Regulatory Role for the mSin3A-HDAC Complex in Pluripotency through Nanog and Sox2* , 2009, Journal of Biological Chemistry.

[21]  Barbara Hero,et al.  Histone Deacetylase 8 in Neuroblastoma Tumorigenesis , 2009, Clinical Cancer Research.

[22]  N. L. Thangue,et al.  Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas , 2008, Nature Clinical Practice Oncology.

[23]  C. Tsien,et al.  Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Tsien,et al.  EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Yu Ning,et al.  Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion , 2008, Laboratory Investigation.

[26]  A. Forastiere,et al.  Head and neck cancer: changing epidemiology, diagnosis, and treatment. , 2008, Mayo Clinic proceedings.

[27]  Dajun Yang,et al.  Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition , 2008, Proceedings of the National Academy of Sciences.

[28]  A. Cmelak,et al.  Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.

[29]  G. Draetta,et al.  Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation , 2007, Molecular and Cellular Biology.

[30]  P. Marks,et al.  Discovery and development of SAHA as an anticancer agent , 2007, Oncogene.

[31]  K. Zatloukal,et al.  Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells , 2006, Molecular Cancer Therapeutics.

[32]  E. Ho,et al.  Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice , 2006 .

[33]  M. Salto‐Tellez,et al.  Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1 , 2005, Cell Death and Differentiation.

[34]  S. Payne,et al.  Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. , 2005, Cancer research.

[35]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[36]  Ping Zhu,et al.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.

[37]  Ivan V. Gregoretti,et al.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. , 2004, Journal of molecular biology.

[38]  Ricky W Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? , 2003, Cancer cell.

[39]  S. K. Zaidi,et al.  Runx2 (Cbfa1, AML-3) Interacts with Histone Deacetylase 6 and Represses the p21CIP1/WAF1 Promoter , 2002, Molecular and Cellular Biology.

[40]  H. Scher,et al.  The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[42]  Brachman Dg,et al.  Molecular biology of head and neck cancer. , 1994, Seminars in oncology.

[43]  L. Ngo,et al.  Potent cytodifferentiating agents related to hexamethylenebisacetamide. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[44]  F. Demard,et al.  Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. , 1988, European journal of cancer & clinical oncology.

[45]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[46]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[47]  M. Gapany.  Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States , 2012 .

[48]  E. Seto,et al.  Deacetylation of nonhistone proteins by HDACs and the implications in cancer. , 2011, Handbook of experimental pharmacology.

[49]  J. Debus,et al.  Long-term outcome and patterns of failure in patients with advanced head and neck cancer , 2011 .

[50]  宮地 充.  Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells , 2010 .

[51]  E. Olson,et al.  The many roles of histone deacetylases in development and physiology: implications for disease and therapy , 2009, Nature Reviews Genetics.

[52]  A. Harel-Bellan,et al.  Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. , 2002, Advances in cancer research.

[53]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[54]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.